Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  1998-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.97.22.2213PMID 9631870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.

  1997cited by this paper
• Immunoelectron microscopic localization of plasminogen activator inhibitor type 1 (PAI-1) in smooth muscle cells from morphologically normal and atherosclerotic human arteries.

  1997cited by this paper
• Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

  1997cited by this paper
• Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherogenesis.

  1997cited by this paper
• Changes in arterial expression of fibrinolytic system proteins in atherogenesis.

  1997cited by this paper
• Determinants of coronary vascular disease in patients with type ii diabetes mellitus and their therapeutic implications

  1997cited by this paper
• Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators.

  1997cited by this paper
• Altered fibrinolysis and platelet function in the development of vascular complications of diabetes

  1996cited by this paper
• Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction.

  1996cited by this paper
• Synergistic augmentation of expression of plasminogen activator inhibitor type‐1 induced by insulin, very‐low-density lipoproteins, and fatty acids

  1996cited by this paper
• Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.

  1996cited by this paper
• Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice

  1996cited by this paper
• Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert.

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

  1995cited by this paper
• Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

  1994cited by this paper
• Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients

  1994cited by this paper
• Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI‐1) Activity and Proinsulin‐like Molecules Independently of Glycaemic Control

  1993cited by this paper
• Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states

  1991cited by this paper
• Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.

  1990cited by this paper
• Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin

  1989cited by this paper
• Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension.

  1989cited by this paper
• Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

  1986cited by this paper
• Insulin secretion, insulin resistance, and obesity.

  1982cited by this paper

• Iatrogenic Hypoglycemia in Type 2 Diabetes Affects Endothelial Proteins Involved in Cardiovascular Dysfunction

  2026cites this paper
• Triglyceride-glucose body mass index predicts prognosis in patients with ST-elevation myocardial infarction

  2024cites this paper
• Circadian rhythm of plasminogen activator inhibitor-1 and cardiovascular complications in type 2 diabetes

  2023cites this paper
• Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients

  2023cites this paper
• Machine Learning for Early Prediction of Major Adverse Cardiovascular Events After First Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: Retrospective Cohort Study

  2023cites this paper
• The Association of Acute Phase Proteins in Stress and Inflammation-Induced T2D

  2022cites this paper
• review on epidemiology, biochemical characteristics, treatment suggestions, and continued studies on diabetes and cardiovascular disease

  2022cites this paper
• High Triglyceride Glucose Index Is Associated with Poor Outcomes in Ischemic Stroke Patients after Reperfusion Therapy

  2021cites this paper
• A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

  2021cites this paper
• Profiles of inflammatory markers and their association with cardiometabolic parameters in rural and urban Uganda

  2021cites this paper
• Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials.

  2020cites this paper
• Awareness of Early Symptoms and Emergency Responses to Myocardial Infarction and Stroke in People with Diabetes Mellitus Compared to Non-diabetic Population in the Community: A Propensity Score-Matched Analysis

  2020cites this paper
• Atherogenesis and Vascular Biology

  2020cites this paper
• Cardiovascular Risk Indices and Their Impact on Outcome in Patients with Hyperglycaemic Emergencies in a Nigerian Hospital.

  2020cites this paper
• 4G/5G Single Nucleotide Polymorphism of Plasminogen Activator Inhibitor-1 Geneis A Novel Diagnostic and Prognostic Marker in ST Elevation Acute Myocardial Infarction in Young Patients

  2019cites this paper
• TXNIP and the GAPDH-Siah1 Signalling Pathway in Diabetic Nephropathy

  2019cites this paper
• Proteoglycan/glycosaminoglycan and collagen content in the arterial wall of patients with end-stage renal disease - new indicators for vascular disease.

  2019cites this paper
• Proteoglycan / glycosaminoglycan and collagen content in the arterial wall of patients with end ‑stage renal disease: new indicators of vascular disease

  2019cites this paper
• HUBUNGAN PENGENDALIAN GLUKOSA DARAH DAN MORNING BLOOD PRESSURE SURGE DENGAN KEJADIAN PENYAKIT JANTUNG KORONER PADA PASIEN DIABETES MELITUS TIPE 2 DI RUMAH SAKIT UMUM CUT MEUTIA

  2019cites this paper
• Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery

  2019cites this paper
• Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Level-An Novel Prognostic Biomarker in ST Elevation Acute Myocardial Infarction among Young South Indian Patients

  2019cites this paper
• The ameliorating effect of carotenoid rich fraction extracted from Dunaliella salina microalga against inflammation- associated cardiac dysfunction in obese rats

  2019cites this paper
• Integral role of receptor for advanced glycation end products (RAGE) in nondiabetic atherosclerosis.

  2019cites this paper
• Apoptotic cell death in heart failure associated with diabetes

  2019cites this paper
• Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial

  2019cites this paper
• Herbal Approach for the Management of Obesity – A Review

  2018cites this paper
• Association of SERPINE1 rs6092 with type 2 diabetes and related metabolic traits in a Chinese population.

  2018cites this paper
• Hemostasis at Extremes of Body Weight

  2018cites this paper
• Primary and secondary prevention in diabetic patients: are we not aggressive enough?

  2017cites this paper
• Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus

  2017cites this paper
• Cardiovascular disease as one of the main complication of uncontrolled diabetes

  2017cites this paper
• Aspects of Plasminiogen Activator Inhibitor 1 in Metabolic Syndrome

  2016cites this paper
• Metabolic Syndrome Fiber Treating Metabolic Syndrome

  2016cites this paper
• Platelet dependent thrombosis, blood thrombogenicity and response to antiplatelet therapy in health, ageing and type 2 diabetes mellitus

  2016cites this paper
• Diabetes Mellitus and Cardiovascular Risk : epidemiology, etiology and intervention

  2016cites this paper
• Understanding Diabetes Mellitus: Pathophysiology

  2016cites this paper
• Role of microRNA-21 in the regulation of human saphenous vein smooth muscle cell function and vascular remodelling.

  2016cites this paper
• The role of Toxoplasma gondii as a possible inflammatory agent in the pathogenesis of type 2 diabetes mellitus in humans

  2016cites this paper
• Proteomic and Genomic Aspects of the Thrombotic Status found in Type 2 Diabetes Mellitus

  2016cites this paper
• Correlation between the plasma fibrinogen concentration and coronary heart disease severity in Moroccan patients with type 2 diabetes. Prospective study.

  2016cites this paper
• Aging: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer's Disease

  2016cites this paper
• M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes

  2015cites this paper
• 4G/4G PAI-1 gene variant in a patient with non-healing ulcers

  2015cites this paper
• Fibroblast growth factor-2 did not restore plasminogen system activity in endothelial cells on glycated collagen

  2015cites this paper
• Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity

  2015cites this paper
• PAI-1 4 G / 5 G polymorphism and coronary artery disease risk : a meta-analysis

  2015cites this paper
• PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.

  2015cites this paper
• The Effects of Systemic Infusion of Bradykinin on Experimental Peritoneal Fibrosis

  2015cites this paper
• ASSESSMENT OF THROMBOPHILIC STATUS IN TYPE 2 DIABETIC PATIENTS: THE LINK BETWEEN PAI-1 POLYMORPHISM AND THE ONSET OF COMPLICATIONS

  2015cites this paper
• Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients.

  2015cites this paper
• Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity

  2015cites this paper
• Implication des macrophages M1/M2 dans les pathologies vasculaires et valvulaires humaines

  2015cites this paper
• Diabetes and Heart Disease

  2015cites this paper
• Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research.

  2015cites this paper
• Small Molecule PAI-1 Functional Inhibitor Attenuates Vascular Smooth Muscle Cell Migration and Survival: Implications for the Therapy of Vascular Disease.

  2014cites this paper
• Coronary Angiographic Findings in Diabetic Patients Versus non-Diabetics with Coronary Heart Disease

  2014cites this paper
• Role of Plasminogen Activator Inhibitor-1 in Senescence and Aging

  2014cites this paper
• Prevalence of Symptomatic Intracranial Atherosclerosis in Caucasians: A Prospective, Multicenter, Transcranial Doppler Study

  2014cites this paper
• The growth factor effect on endothelial cell dysfunction in the presence of glycated collagen and Abeta peptide: implications for decreased angiogenesis in diabetes and Alzheimer's disease

  2014cites this paper
• High-Sensitivity C-reactive protein and Plasminogen Activator Inhibitor 1 as markers of cardiovascular risk in Egyptian obese adolescents

  2014cites this paper
• Metabolism and the circadian clock converge.

  2013cites this paper
• In vitro assessment of the anti-diabetic activity of Sclerocarya birrea and Ziziphus mucronata

  2013cites this paper
• Common Genetic Determinants of Coagulation and Fibrinolysis

  2013cites this paper
• Influence of admission glucose profile and hemoglobin A1c on complications of acute myocardial infarction in diabetic patients.

  2013cites this paper
• Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients.

  2013cites this paper
• Fiber Treating Metabolic Syndrome

  2013cites this paper
• International Journal of Interventional Cardioangiology

  2013cites this paper
• Significance of vitronectin and PAI-1 activity levels in carotid artery disease: comparison of symptomatic and asymptomatic patients.

  2013cites this paper
• Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome

  2013cites this paper
• The influence of vitamin E bonded haemodialysis membranes on erythropoiesis stimulating agent requirements, oxidative stress, inflammation, haemostasis and outcomes

  2013cites this paper
• Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus

  2013cites this paper
• Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients.

  2013cites this paper
• Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist.

  2012cites this paper
• Diabetes and coronary artery disease: the importance of glycemic control

  2012cites this paper
• Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis

  2012cites this paper
• Dronedarone reduces arterial thrombus formation

  2012cites this paper
• How to Best Manage Glycemia and Non-Glycemia During the Time of Acute Myocardial Infarction

  2012cites this paper
• PAI-1 and Diabetes: A Journey From the Bench to the Bedside

  2012cites this paper
• The Prothrombotic Tendency in Metabolic Syndrome: Focus on the Potential Mechanisms Involved in Impaired Haemostasis and Fibrinolytic Balance

  2012cites this paper
• Effects of High and Low Molecular Weight Chitosan on Plasma Cholesterol, Glucose and Adipocytokines in Diabetic Rats Induced by Streptozotocin and Nicotinamide

  2012cites this paper
• p38 Mitogen-activated protein kinase is required for glucosamine-induced endothelial nitric oxide synthase uncoupling and plasminogen-activator inhibitor expression.

  2012cites this paper
• [The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].

  2012cites this paper
• Effects of High Glucose and Ketosis (Acetoacetate, ß-Hydroxybutyrate) on PAI-1 Secretion in Human Umbilical Vascular Endothelial Cells

  2011cites this paper
• Metabolic Factors , Adipose Tissue , and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes Findings From the Look AHEAD Study

  2011cites this paper
• Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial

  2011cites this paper
• The effects of genes, environment and ethnicity on insulin resistance and obesity in aboriginal and non-aboriginal South American populations

  2011cites this paper
• Evaluating coronary artery disease in type 2 diabetes mellitus and Other Risk Factors by angiographic study

  2011cites this paper
• Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes: Findings From the Look AHEAD Study

  2011cites this paper
• The Role of Immunogenicity in Cardiovascular Disease.

  2011cites this paper
• Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications

  2011cites this paper
• Diabetes Mellitus and Cardiovascular Disease

  2011cites this paper
• DIABETIC STUDIES The Review of Effects of Different Protein Sources on Plasminogen Inhibitor-1 and Factor VII Coagulant Activity Added to a Fat-Rich Meal in Type 2 Diabetes

  2011cites this paper
• Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

  2010cites this paper
• Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision

  2010cites this paper
• Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.

  2010cites this paper
• Involvement of RAGE, NADPH oxidase, and Ras/Raf-1 pathway in glycated LDL-induced expression of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells.

  2010cites this paper
• Effects of different protein sources on plasminogen inhibitor-1 and factor VII coagulant activity added to a fat-rich meal in type 2 diabetes.

  2010cites this paper
• Iconography : Quelle place pour l’aspirine en prévention cardiovasculaire primaire chez le diabétique en 2010 ?

  2010cites this paper
• A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.

  2009cites this paper
• The prognostic value of blood glucose level on admission in non-diabetic patients with acute myocardial infarction

  2009cites this paper